# Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer

> **NCT07565857** · NA · NOT_YET_RECRUITING · sponsor: **Natera, Inc.** · enrollment: 1000 (estimated)

## Conditions studied

- Gastric-Esophageal Cancer

## Interventions

- **DEVICE:** Signatera Genome ultra-sensitive ctDNA blood test

## Key facts

- **NCT ID:** NCT07565857
- **Lead sponsor:** Natera, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2028-09
- **Final completion:** 2034-09
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07565857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07565857, "Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07565857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*